Navigation Links
Biomerix Corporation Reaches European Distribution Agreement with Cellon S.A.
Date:5/18/2011

FREMONT, Calif., May 18, 2011 /PRNewswire/ -- Biomerix Corporation and Cellon today announced a strategic distribution agreement for the Biomerix 3D Scaffold, a novel three-dimensional tissue scaffold. Under the agreement, Cellon will market and distribute the Biomerix 3D Scaffold to research institutions across Europe.

Comprised of a non-degradable, three-dimensional, open-cell polycarbonate polyurethane, the Biomerix 3D Scaffold is designed to mimic the nature and function of the extracellular matrix (ECM). Its novel macroporous microarchitecture consists of a network of interconnecting cells and pores, creating an environment highly conducive to applications in regenerative medicine, drug discovery, and stem cell research.  The unique chemistry and microarchitecture of the Biomerix 3D Scaffold has been demonstrated to support optimal cell proliferation and superior cell viability in both in-vitro and in-vivo studies involving diverse cell types, including hematopoetic stem cells, mesenchymal stem cells, induced pluripotent stem cells, human adipose stem cells, human osteoblasts, fibroblasts, and fibrochondrocytes.

"Biomerix is delighted to form this new strategic partnership with Cellon, further strengthening each company's European presence in the field of regenerative medicine, tissue engineering, and drug discovery, development and delivery.  The proprietary Biomerix Biomaterial used to manufacture the Biomerix 3D Scaffold has received seven US and international regulatory clearances for different indications in soft tissue repair, orthopedics, and vascular embolization," said Kenneth Hayes, President and Chief Executive Officer of Biomerix Corporation.

About Biomerix Corporation

Biomerix Corporation is recognized as a leader in the development and manufacturing of innovative non-absorbable and bioresorbable three-dimensional, open-cell, resilient elastomeric polyurethane biomaterials.  The Company's expertise includes the development, co-development and supply of new proprietary materials, products and components to customers in the medical, industrial and consumer industry markets.

For more information please visit www.biomerix.com or call 888.308.3620.

About Cellon S.A.

CELLON is a rapidly growing company, established in 1987 to provide products and services to the vaccine production and bioprocessing industries. Areas of expertise include mammalian cell culture processes and the storage & transport of sterile liquids. Our success to-date has been built upon an understanding of the requirements of this demanding business sector - which has led to the formation of many collaborative relationships with our customers. Such partnerships have enabled us to develop a range of products to meet specific industry needs - in unique, often revolutionary, ways.

For more information please visit www.cellon.lu.


'/>"/>
SOURCE Biomerix Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Biomerix Granted US Patent for Its Proprietary Biomaterial Platform Technology
2. Biomerix Corporation Announces FDA Clearance and Market Launch of REVIVE(TM) for Use in Soft Tissue Repair Procedures
3. Designed by Kids, Built by Volunteers: Roche, New Jersey Community Development Corporation, and KaBOOM! Build New Playground in Just One Day for Paterson Public School Children
4. Geminus Corporation Named Recipient of Second Annual Netsmart Technologies Customer Innovation Award
5. Terumo Americas Holding, Inc., Agrees to Acquire Harvest Technologies Corporation, a Leader in the Development of Point-of-Care Cellular Therapy
6. DURECT Corporation Announces First Quarter 2011 Financial Results and Update of Programs
7. Techne Corporation Declares Dividend
8. Techne Corporation Announces Acquisition
9. SynapDx Corporation Licenses Autism Diagnostic Discoveries From Childrens Hospital Boston
10. Vestaron Corporation Announces New Leadership
11. Mitsubishi Chemical Corporation Signs Memorandum of Understanding for Strategic Partnership With Genomatica for Sustainable Chemicals in Asia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), a ... targeted antiviral therapies, announced today that it will present ... held February 8-9, 2016, at the Waldorf Astoria New ... Healthcare Conference, taking place in New York ... Sapirstein , Chief Executive Officer of ContraVir, will provide ...
(Date:2/4/2016)... Brooklyn, NY (PRWEB) , ... February 04, 2016 , ... ... cuvettes for over 10 years. What sets them apart from other cuvette ... that is posted on their website. On top of this steady flow of ...
(Date:2/3/2016)... and HOLLISTON, Mass., Feb. 3, 2016 Harvard ... a biotechnology company developing bioengineered organ implants for ... today announced that CEO Jim McGorry , ... Investor Conference on Tuesday, February 9, 2016 ... York City . HART,s presentation will be ...
(Date:2/3/2016)... , ... February 03, 2016 , ... ... annual report which summarizes and analyzes nearly 750 unique supply chain ... alert, and analysis service. , Supply chain risk management practitioners subscribe to ...
Breaking Biology Technology:
(Date:1/18/2016)... 2016  Extenua Inc., a pioneering developer of ... and access of ubiquitous on-premise and cloud storage, today ... Cyber.  ... C4ISR and Cyber initiatives in support of National ... technology solutions," said Steve Visconti , Extenua ...
(Date:1/11/2016)...  higi, the leading retail and omni-channel community engagement ... and mobile, today announced it has closed funding ... --> --> ... higi,s health platform – its network of health ... expanding services and programs to retail partners and ...
(Date:1/7/2016)... , Jan. 7, 2016  A United States ... the first court in the country to interpret a ... lawsuit to go forward against the photo website Shutterfly ... BRIAN NORBERG vs. SHUTTERFLY, INC.; and ... plaintiff alleges that Shutterfly violates the Illinois Biometric Privacy ...
Breaking Biology News(10 mins):